Form 4: Bristol-Myers Squibb Exec Reports Equity Transactions

Bristol-Myers Squibb EVP Wendy Short Bartie reported significant equity transactions, including vesting of market share units and performance shares, and new grants.

Summary

• Wendy Short Bartie, EVP, Corporate Affairs of Bristol-Myers Squibb Co (BMY), reported multiple equity transactions on March 10, 2026.
• Acquired 639 shares of common stock from the vesting of market share units granted on March 10, 2022.
• Acquired 749 shares of common stock from the vesting of market share units granted on March 10, 2023.
• Acquired 4,495 shares of common stock from the distribution of performance shares earned under the 2023-2025 Long-Term Performance Award.
• Disposed of a total of 153 shares (72 and 81 shares) due to downward adjustments based on performance factors for market share units.
• Disposed of a total of 1,275 shares (205, 242, and 828 shares) withheld for tax payments upon award vesting, at a price of $60.13 per share.
• Received new grants of 6,531 market share units, which are scheduled to cliff vest on March 10, 2029.
• Received new grants of 9,796 performance shares, scheduled for distribution on March 10, 2029.
• Following these transactions, beneficial ownership of common stock is 7,917 shares.
• Beneficial ownership of derivative securities includes 750 market share units (from the 2023 grant), 6,531 new market share units, and 9,796 new performance shares.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a standard disclosure of executive equity compensation, reflecting the ongoing operation of long-term incentive plans and not indicating any new material operational or financial developments.

Positives

• Vesting of 639 market share units from a 2022 grant, converting into common stock.
• Vesting of 749 market share units from a 2023 grant, converting into common stock.
• Distribution of 4,495 performance shares earned under the 2023-2025 Long-Term Performance Award.
• Grant of 6,531 new market share units, aligning executive incentives with future company performance.
• Grant of 9,796 new performance shares, further aligning executive incentives with future company performance.

Negatives

• Downward adjustment of 153 shares (72 and 81 shares) due to performance factors applied to market share units, indicating performance did not reach maximum targets.
• Withholding of 1,275 shares for tax payments upon vesting of awards, reducing the net shares received by the executive.

Future Outlook

New market share units are scheduled to cliff vest on March 10, 2029, and new performance shares are set for distribution on the same date, subject to performance certification by the Board.

Industry Context

StockSavvy.ai notes these are routine executive compensation transactions common in the pharmaceutical industry, reflecting the operation of long-term incentive plans designed to align executive interests with shareholder value.

Comparison to Industry Standards

• StockSavvy.ai observes that equity compensation structures involving market share units and performance shares with performance factors and relative Total Shareholder Return (rTSR) components are standard practice among large pharmaceutical companies like Pfizer or Merck.
• The use of payout factors (80%-225%) and rTSR floors for market share units is a common mechanism to incentivize performance while providing a minimum payout in specific market conditions, similar to practices seen across the S&P 500.

Stakeholder Impact

• Shareholders: Experience minor dilution from the issuance of shares upon vesting of awards, but also benefit from the alignment of executive incentives with long-term company performance.
• Employees: No direct impact on the broader employee base is indicated by this executive compensation filing.

Next Steps

• Certification of performance results by the Board for the newly granted market share units and performance shares.
• Cliff vesting of 6,531 market share units on March 10, 2029.
• Distribution of 9,796 performance shares on March 10, 2029.

Key Dates

Recommendation

This Form 4 filing details routine executive equity compensation transactions, including vesting of existing awards and grants of new ones. It does not provide new fundamental information about Bristol-Myers Squibb's operational performance or strategic direction that would warrant a change in investment recommendation. The transactions are expected and reflect standard long-term incentive plans.

Keywords

Bristol-Myers Squibb, BMY, Form 4, Insider Transaction, Equity Compensation, Market Share Units, Performance Shares, Executive Compensation, Stock Vesting